Cadrenal Therapeutics, Inc.
CVKD evidence brief
What we can confirm
- BioSniper Score:
- 5.7 / 10
- Market Cap:
- $3.4M
- Lead Asset:
- cad-1005 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for CVKD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CVKD
Cadrenal Therapeutics, Inc. (CVKD) is a late-stage biopharmaceutical company developing specialized therapies for critical care cardiology and orphan cardiovascular conditions, with a focus on thrombo-inflammatory and anticoagulation indications.
Key risk: Cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$3.4M
Cash Runway
—
Lead Asset
cad-1005 (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Cadrenal Therapeutics, Inc..
Cadrenal Therapeutics, Inc. (CVKD) is a late-stage biopharmaceutical company developing specialized therapies for critical care cardiology and orphan cardiovascular conditions, with a focus on thrombo-inflammatory and anticoagulation indications.
- Lead asset CAD-1005 has Orphan Drug and Fast Track designations from the FDA for heparin-induced thrombocytopenia (HIT) and orphan status from the EMA [sec · filed 2026-07-13].
- As of June 30, 2026, the company reported cash and cash equivalents of $2.4 million and a net loss of $3.3 million for the period [latest reported financials].
- In August 2026, the company announced FDA alignment on the primary endpoint and path forward for a Phase 3 registration study of CAD-1005 in HIT [news · published 2026-08-31].
- The company has retained Tungsten Advisors to lead a formal strategic process to maximize value, including potential partnerships or other strategic transactions [news · published 2026-10-07].
- The pipeline includes tecarfarin, a late-stage oral vitamin K antagonist, and preclinical asset CAD-2000, a 12-LOX inhibitor for chronic cardiorenal indications [sec · filed 2026-07-13][sec_mda · as of 2026-08-13].
What works
- CAD-1005 has achieved regulatory alignment with the FDA on a Phase 3 registrational path, reducing clinical risk for the lead program [news · published 2026-08-31].
- The company has received Orphan Drug and Fast Track designations from the FDA for CAD-1005, which may provide market exclusivity and development incentives [sec · filed 2026-07-13].
- The strategic retention of Tungsten Advisors indicates active efforts to monetize or partner the portfolio, potentially providing non-dilutive capital [news · published 2026-10-07].
What to weigh
- As of June 30, 2026, the company had only $2.4 million in cash, with a net loss of $3.3 million, indicating a very limited operating runway [latest reported financials].
- The company has stated that if it cannot secure strategic partnerships or funding within twelve months, it may be forced to delay programs, liquidate assets, or cease operations [sec_mda · as of 2026-08-13].
- The company has incurred recurring losses since inception and relies on periodic equity and debt financings to fund operations, creating ongoing dilution risk [sec_mda · as of 2026-08-13].
- The Phase 3 trial protocol for CAD-1005 remains subject to final FDA meeting minutes and further comments, leaving some regulatory uncertainty [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
FDA alignment on Phase 3 path for CAD-1005
“FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study”
News · August 31, 2026
Risk of ceasing operations without partnerships
“If we are unable to secure strategic partnerships, out-licensing agreements, or alternative non-dilutive funding such as grant funding within the next twelve months, we will lack the financial resources to sustain our operations.”
SEC MD&A · August 13, 2026
Retention of Tungsten Advisors for strategic process
“Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics”
News · October 7, 2026
Risks & what to watch (4)›
Key risks
- Cash runway — Cash of $2.4M as of 2026-06-30 with ongoing net losses may only fund operations for a few months [latest reported financials].
- Going concern risk
- Regulatory uncertainty
- Dependence on partnerships
What to watch
- Outcome of the strategic process led by Tungsten Advisors, including potential partnership or acquisition announcements [news · published 2026-10-07].
- Finalization of the Phase 3 protocol for CAD-1005 and initiation of the pivotal trial [sec_mda · as of 2026-03-31].
- Cash position and any new financing or capital raises in upcoming quarters [latest reported financials].
- Progress of preclinical asset CAD-2000 and any updates on the Cardiac Acute Critical Care Franchise strategy [sec_mda · as of 2026-08-13].
Sources: News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Cadrenal Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cadrenal Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.37 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 22 sells (180d)
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 2.1%
- Days to cover
- 1.1
- Shares short
- 54,350
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CVKD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cadrenal Therapeutics, Inc.?
Cadrenal Therapeutics, Inc. (CVKD) is a late-stage biopharmaceutical company developing specialized therapies for critical care cardiology and orphan cardiovascular conditions, with a focus on thrombo-inflammatory and anticoagulation indications.
What is Cadrenal Therapeutics, Inc.'s lead drug candidate?
Cadrenal Therapeutics, Inc.'s most advanced tracked candidate is cad-1005 (Phase 3) for heparin-induced thrombocytopenia ("HIT").
Who is the CEO of Cadrenal Therapeutics, Inc.?
Mr. Quang X. Pham is the chief executive officer of Cadrenal Therapeutics, Inc. (CVKD).
Where is Cadrenal Therapeutics, Inc. headquartered?
Cadrenal Therapeutics, Inc. (CVKD) is headquartered in Ponte Vedra, FL, United States.
What therapeutic areas does Cadrenal Therapeutics, Inc. focus on?
Cadrenal Therapeutics, Inc. develops therapies across Cardiovascular, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.